Clinical Trial Update: A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SHC014748M in relapsed or refractory Peripheral T Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• SHC014748M

Snippet

Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: UNKNOWN